Assessing Penumbra after recent share performance
Penumbra (PEN) has drawn attention after a mixed stretch for the stock, with a small move over the past week, a modest decline over the past month, and a positive total return over the past year.
See our latest analysis for Penumbra.
The current share price of $336.42 sits against a 90 day share price return of 6.14% and a 1 year total shareholder return of 24.78%, suggesting momentum has been building over the longer stretch.
If Penumbra’s move has caught your eye, it can be useful to see what else is setting up in the market by scanning 36 healthcare AI stocks.
With Penumbra trading at $336.42 and analyst targets pointing to $360.13, along with recent revenue and net income growth, should you view current levels as a reasonable entry point, or assume the market is already pricing in future growth?
Most Popular Narrative: 6.6% Undervalued
The most followed narrative pegs Penumbra’s fair value at $360.13, slightly above the last close of $336.42, which sets up a modest upside case built on specific growth drivers.
The soon to be released STORM PE randomized trial is poised to provide Level 1 evidence comparing Penumbra's thrombectomy technology to standard anticoagulation for pulmonary embolism; a positive outcome could expand guideline adoption, significantly accelerate procedure volumes, and drive substantial revenue growth by rapidly increasing penetration in a very underpenetrated, large market.
Curious what kind of revenue lift, margin profile, and earnings power would need to line up behind that view? The narrative builds a detailed, multi year roadmap for those assumptions.
Result: Fair Value of $360.13 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on clinical and execution risk, with outcomes from trials like STORM PE and pressure on margins from higher R&D and sales spend both potential spoilers.
Find out about the key risks to this Penumbra narrative.
Another Angle: Multiples Paint a Tougher Picture
While the narrative-backed fair value of $360.13 suggests a 6.6% undervaluation, the current P/E of 74.3x is far above the US Medical Equipment industry at 27.6x, the peer average at 34.9x, and an estimated fair ratio of 29.5x. This points to meaningful valuation risk instead.
For a closer look at what this gap could mean if sentiment or growth expectations cool, check the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of optimism and valuation risk feels conflicting, do not wait on others to decide the story for you. Review the 2 key rewards
Looking for more investment ideas?
If Penumbra is on your radar, do not stop there. Broaden your watchlist now so you are not relying on a single story.
- Target higher yield opportunities by checking income candidates that show up in the 12 dividend fortresses.
- Hunt for quality at a sensible price by reviewing companies highlighted in the 61 high quality undervalued stocks.
- Prioritise resilience by scanning stocks featured in the 69 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com